Prostate Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Prostate Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month13 studies across 10 companies, in the next 180 days.
August 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corporation | SpaceIT Hydrogel System for Perirectal SpacingNCT06451614Primary Safety Endpoint - Acute Grade 3 or greater adverse events. | Not applicable | Active, not recruiting | 2026-08-30 | in 10 d | 2026-08-12 |
| CADL | Candel Therapeutics, Inc. | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000Biodistribution of aglatimagene besadenovec | Phase 2 | Recruiting | Aug 2026 | ≤ 11 d | 2026-03-20 |
| EXEL | Exelixis | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092 | Phase 1 | Active, not recruiting | 2026-08-31 | in 11 d | 2024-11-19 |
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
September 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsNCT04557449Number of participants with dose limiting toxicities in the Dose Escalation Portion | Phase 2 | Active, not recruiting | 2026-09-23 | in 34 d | 2025-10-01 |
| ISRG | Intuitive Surgical | CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical ProstatectomyNCT07666217observationalIncidence of postoperative complications and Clavien-Dindo Grade 3a or higher postoperative complications | — | Active, not recruiting | 2026-09-30 | in 41 d | 2026-06-24 |
October 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AMGN | Amgen | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerNCT06555796Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | 2026-10-08 | in 49 d | 2026-01-26 |
| TEM | Tempus AI | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | 2026-10-19 | in 60 d | 2025-05-06 |
| IDYA | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-13 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Study of AZD0754 in Participants With Metastatic Prostate CancerNCT06267729Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs). | Phase 1/2 | Recruiting | 2026-11-24 | in 96 d | 2026-02-23 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779Radiographic Progression Free Survival (rPFS) | Phase 3 | Recruiting | 2026-12-02 | in 104 d | 2026-08-14 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)NCT06380738observationalTime to treatment discontinuation | — | Recruiting | 2027-02-14 | in 178 d | 2026-07-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Prostate Cancer
most recently updated first391 studies match. Showing the first 100 of 391 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| AZN | AstraZeneca | — | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerNCT03732820results2023-06-15Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment | Phase 3 | Active, not recruiting | Drug: olaparib, abiraterone acetate | Metastatic Castration-resistant Prostate Cancer | 895 | 2018-10-31 | 2021-07-30actual | — | 2026-08-18 |
| AZN | AstraZeneca | — | Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDerationNCT07052578observationalProportion of patients received any ADT | — | Recruiting | — | Prostate Cancer | 400 | 2025-06-30 | 2028-11-30 | in 833 d | 2026-08-18 |
| EXEL | Exelixis | $13.2B | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Enrolling by invitation | Drug: Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide | Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer | 5,000 | 2026-07-30 | 2030-05-31 | in 1,380 d | 2026-08-18 |
| PFE | Pfizer | $155.3B | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622radiological Progression-Free Survival | Phase 3 | Active, not recruiting | Drug: talazoparib plus enzalutamide, Placebo plus enzalutamide | Prostate Cancer | 599 | 2021-05-12 | 2026-02-18actual | — | 2026-08-17 |
| KYNB | Kyntra Bio | $28M | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06842498Radiographic Progression-free Survival (rPFS) By Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria | Phase 2 | Recruiting | Drug: FG-3246 | Metastatic Castration-Resistant Prostate Cancer | 75 | 2026-02-22 | 2028-03-31 | in 589 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779Radiographic Progression Free Survival (rPFS) | Phase 3 | Recruiting | Drug: PF-06821497, Placebo, Enzalutamide | Metastatic Castration-Resistant Prostate Cancer | 900 | 2024-10-22 | 2026-12-02 | in 104 d | 2026-08-14 |
| PFE | Pfizer | $155.3B | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853Radiographic Progression Free Survival (rPFS) | Phase 3 | Recruiting | Drug: Mevrometostat, Placebo, Enzalutamide | Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate | 1,000 | 2025-09-28 | 2028-09-12 | in 754 d | 2026-08-14 |
| AZN | AstraZeneca | — | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR) | Phase 2 | Recruiting | Drug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | 454 | 2022-09-06 | 2027-10-01 | in 407 d | 2026-08-13 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)NCT05519449Incidence of Dose Limiting Toxicities (DLT) | Phase 1 | Recruiting | Biological: JANX007 · Drug: Darolutamide | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer | 272 | 2022-09-15 | Jul 2027 | ≤ 345 d | 2026-08-13 |
| AMGN | Amgen | $229.9B | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674OS | Phase 3 | Recruiting | Drug: Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel | Metastatic Castration-resistant Prostate Cancer | 750 | 2025-11-28 | 2030-01-07 | in 1,236 d | 2026-08-13 |
| BSX | Boston Scientific Corporation | $73.1B | Effectiveness of the SpaceOAR Vue System in Subjects With Prostate CancerNCT04905069Late Gastrointestinal (GI) Toxicity | Not applicable | Active, not recruiting | Device: SpaceOAR Vue System | Prostate Cancer | 500 | 2021-12-21 | Dec 2027 | ≤ 498 d | 2026-08-12 |
| BSX | Boston Scientific Corporation | $73.1B | SpaceIT Hydrogel System for Perirectal SpacingNCT06451614Primary Safety Endpoint - Acute Grade 3 or greater adverse events. | Not applicable | Active, not recruiting | Device: SpaceIT Hydrogel System, Commercially available Boston Scientific Spacer | Prostate Cancer | 230 | 2024-10-30 | 2026-08-30 | in 10 d | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerNCT06067841Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: BMS-986460 | Metastatic Castration-resistant Prostate Cancer | 140 | 2023-10-18 | 2029-08-24 | in 1,100 d | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| AZN | AstraZeneca | — | A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsNCT07336446Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only) | Phase 1/2 | Recruiting | Drug: AZD9750, AZD5305 | Prostate Cancer | 300 | 2026-01-27 | 2029-01-26 | in 890 d | 2026-08-10 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has SpreadNCT07543055Occurrence of Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Genetic: BPX-601 | Prostate Cancer | 36 | 2026-08-10 | 2030-02-05 | in 1,265 d | 2026-08-10 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate CancerNCT07545811Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Biological: JANX014 | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer | 43 | 2026-04-15 | May 2028 | ≤ 650 d | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerNCT03706365results2025-03-06Radiographic Progression Free Survival (rPFS) | Phase 2/3 | Active, not recruiting | Drug: Abemaciclib, Placebo, Abiraterone acetate, Prednisone | Prostate Cancer | 393 | 2018-11-26 | 2024-01-02actual | — | 2026-08-07 |
| AMGN | Amgen | $229.9B | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerNCT07493512Number of Participants with Treatment-emergent Adverse Events | Phase 1 | Recruiting | Drug: Xaluritamig | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 40 | 2026-04-28 | 2028-01-30 | in 528 d | 2026-08-07 |
| AMGN | Amgen | $229.9B | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerNCT04221542Parts 1-5 and 7: Incidence of Treatment-emergent Adverse Events | Phase 1 | Recruiting | Drug: AMG 509, Abiraterone, Enzalutamide | Prostate Cancer | 479 | 2020-03-04 | 2030-03-22 | in 1,310 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496 | Phase 1 | Recruiting | Drug: LY4257496, Standard of Care Anticancer Therapies · Diagnostic test: LY4257529 | Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms | 421 | 2025-08-06 | Apr 2030 | ≤ 1,349 d | 2026-08-06 |
| AZN | AstraZeneca | — | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerNCT07529717Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE) | Phase 1/2 | Recruiting | Drug: AZD8359, AZD8359, AZD8359, AZD8359 | Metastatic Prostate Cancer | 42 | 2026-05-18 | 2027-11-17 | in 454 d | 2026-08-06 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell CarcinomaNCT07594106Occurrence of Dose Limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 265 | 2026-07-20 | 2030-10-27 | in 1,529 d | 2026-08-05 |
| PRCT | PROCEPT BioRobotics | $1.2B | WATER IV PCa (AS Sub-study)NCT07650448Freedom from GG ≥ 2 | Not applicable | Not yet recruiting | Device: Aquablation Therapy · Other: Active Surveillance | Localized Prostate Cancer | 333 | Sep 2026 | Dec 2028 | ≤ 864 d | 2026-08-04 |
| GLUE | Monte Rosa Therapeutics, Inc | $1.3B | Study of Oral MRT-2359 With Apalutamide in Prostate CancerNCT07745361Assess the efficacy of MRT-2359 combined with apalutamide | Phase 2 | Recruiting | Drug: Oral MRT-2359, Apalutamide | Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma) | 25 | Aug 2026 | Oct 2027 | ≤ 437 d | 2026-08-04 |
| AMGN | Amgen | $229.9B | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerNCT06613100Number of Participants who Experienced Treatment-emergent Adverse Events | Phase 1 | Recruiting | Drug: Xaluritamig, GnRH Antagonist | Prostate Cancer | 40 | 2024-11-25 | 2027-02-17 | in 181 d | 2026-07-31 |
| PFE | Pfizer | $155.3B | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD) | Phase 1 | Recruiting | Drug: Mervometostat (PF-06821497), Enzalutamide, Itraconazole | Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL) | 453 | 2018-04-17 | 2028-04-20 | in 609 d | 2026-07-29 |
| AZN | AstraZeneca | — | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate CancerNCT07192614Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE) | Phase 1/2 | Recruiting | Drug: AZD6621 | Prostate Cancer | 52 | 2025-09-30 | 2029-03-29 | in 952 d | 2026-07-29 |
| AZN | AstraZeneca | — | 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)NCT04553926observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions(ADRs), serious ADRs (SADRs), unexpected AEs/ADRs) | — | Completed | — | Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer | 661 | 2021-02-01 | 2025-07-11actual | — | 2026-07-23 |
| ORIC | ORIC Pharmaceuticals | $1.4B | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)NCT07723248Radiographic Progression Free Survival assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) | Phase 3 | Recruiting | Drug: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel | Metastatic Castration Resistant Prostate Cancer | 600 | Jul 2026 | Mar 2028 | ≤ 589 d | 2026-07-23 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| AZN | AstraZeneca | — | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803Metastasis-free survival (MFS) | Phase 3 | Recruiting | Drug: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT) | Prostate Cancer | 700 | 2025-08-06 | 2033-03-31 | in 2,415 d | 2026-07-21 |
| BNTX | BioNTech SE | — | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerNCT07365995rPFS assessed by BICR | Phase 3 | Recruiting | Drug: BNT324, Docetaxel, Prednisone/prednisolone | Metastatic Castration-resistant Prostate Cancer | 736 | 2026-04-22 | Feb 2031 | ≤ 1,653 d | 2026-07-20 |
| AZN | AstraZeneca | — | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)NCT06380738observationalTime to treatment discontinuation | — | Recruiting | — | Metastatic Castration-resistant Prostate Cancer | 250 | 2024-02-14 | 2027-02-14 | in 178 d | 2026-07-17 |
| AZN | AstraZeneca | — | Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerNCT07181161Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs) | Phase 1/2 | Recruiting | Drug: AZD0516, AZD9574 | Metastatic Prostate Cancer | 177 | 2025-10-01 | 2029-01-18 | in 882 d | 2026-07-15 |
| AKTS | Aktis Oncology, Inc. | — | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerNCT07581184Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519 | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) | Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3 | 138 | Jul 2026 | Dec 2027 | ≤ 498 d | 2026-07-14 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Drug: IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | 216 | 2023-04-18 | Oct 2026 | ≤ 72 d | 2026-07-13 |
| LLY | Eli Lilly and Company | $1.15T | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449results2026-07-09Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin | Phase 1 | Completed | Drug: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin | Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer | 353 | 2013-11-15 | 2019-02-19actual | — | 2026-07-09 |
| PFE | Pfizer | $155.3B | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)NCT02319837results2024-03-25Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide | Phase 3 | Active, not recruiting | Drug: Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label | Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate | 1,068 | 2014-12-17 | 2023-01-31actual | — | 2026-07-09 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsNCT03972657Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: REGN5678, Cemiplimab | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 345 | 2019-08-12 | 2027-11-15 | in 452 d | 2026-07-09 |
| ORIC | ORIC Pharmaceuticals | $1.4B | Study of ORIC-944 in Patients With Metastatic Prostate CancerNCT05413421Recommended Phase 2 Dose (RP2D) | Phase 1 | Recruiting | Drug: ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets | Metastatic Prostate Cancer | 275 | 2022-06-01 | Jun 2027 | ≤ 314 d | 2026-07-09 |
| AZN | AstraZeneca | — | Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsNCT04560452observationalNumber and percentage of patients with AEs as well as number of AE events as assessed by CTCAE | — | Completed | — | Ovarian Cancer, Prostate Cancer | 1,018 | 2021-03-15 | 2025-09-05actual | — | 2026-07-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)NCT05288166results2025-06-27Radiographic Progression-Free Survival (rPFS) Assessed by Investigator | Phase 3 | Active, not recruiting | Drug: Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 925 | 2022-04-14 | 2024-02-15actual | — | 2026-07-01 |
| AZN | AstraZeneca | — | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110Radiographic Progression-Free Survival (rPFS) | Phase 3 | Recruiting | Drug: AZD2265, Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Rezvilutamide, Radium-223 | Metastatic Castration-resistant Prostate Cancer | 670 | 2026-05-04 | 2029-02-13 | in 908 d | 2026-07-01 |
| AZN | AstraZeneca | — | A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.NCT05938270Fold change in % γH2AX positive cells from baseline value in tumour samples | Phase 1 | Completed | Drug: Saruparib (AZD5305), Darolutamide · Other: No Treatment | Prostate Cancer | 113 | 2023-09-21 | 2026-06-15actual | — | 2026-06-30 |
| AZN | AstraZeneca | — | Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerNCT07590934Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs) | Phase 1/2 | Recruiting | Drug: AZD2265 (FPI-2265), AZD9574, Docetaxel, AZD2287 (Imaging agent) | Metastatic Prostate Cancer | 152 | 2026-06-03 | 2029-09-25 | in 1,132 d | 2026-06-30 |
| AZN | AstraZeneca | — | PROLONG (PRostateOLaparibONcombinationGcc) StudyNCT07674121observationalEvaluate the time to treatment discontinuation (TTD) or death (event-free rate) at 6 and 12 months in 1L NHA pre-exposed mCRPC patients treated with Olaparib + Abiraterone. | — | Not yet recruiting | Drug: Olaparib and Abiraterone Combination | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 75 | 2026-06-30 | 2029-09-30 | in 1,137 d | 2026-06-29 |
| LLY | Eli Lilly and Company | $1.15T | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentNCT05999968Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Terminatedsponsor's stated reason: The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary endpoint. | Drug: Abemaciclib, Darolutamide, LHRH agonist/antagonist | Prostatic Neoplasms | 10 | 2024-01-12 | 2024-02-23actual | — | 2026-06-26 |
| AZN | AstraZeneca | — | Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian FederationNCT07146113observationalProportion of patients received any ADT | — | Suspendedsponsor's stated reason: As a part of planned reassessment for the current period, a decision has been made to prioritize, optimize, and reallocate resources. As a result, enrollment and other study activities have been temporarily halted. | — | Prostate Cancer | 400 | 2025-06-30 | 2027-06-30 | in 314 d | 2026-06-26 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based ChemotherapyNCT03641560results2025-01-23Number of Participants With Treatment- Emergent Adverse Events (TEAEs) | Phase 4 | Completed | Drug: Enzalutamide, Androgen deprivation therapy (ADT) | Metastatic Castration Resistant Prostate Cancer | 52 | 2018-09-19 | 2024-02-20actual | — | 2026-06-24 |
| ISRG | Intuitive Surgical | $138.2B | CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical ProstatectomyNCT07666217observationalIncidence of postoperative complications and Clavien-Dindo Grade 3a or higher postoperative complications | — | Active, not recruiting | — | Prostate Cancer | 625 | 2026-03-26 | 2026-09-30 | in 41 d | 2026-06-24 |
| AZN | AstraZeneca | — | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)NCT05171816results2025-06-29Radiological Progression Free Survival (rPFS) | Phase 3 | Active, not recruiting | Drug: olaparib, abiraterone acetate | Metastatic Castration-resistant Prostate Cancer | 110 | 2021-06-24 | 2024-01-22actual | — | 2026-06-18 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalation | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2026-02-24 | 2027-07-30 | in 344 d | 2026-06-18 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerNCT06318273Percentage of Participants With Adverse Events (AEs) | Phase 1 | Active, not recruiting | Drug: ABBV-969 | Metastatic Castration-Resistant Prostate Cancer | 152 | 2024-03-08 | May 2027 | ≤ 284 d | 2026-06-17 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsNCT07540572Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation | Phase 1 | Recruiting | Drug: IDE574, Fulvestrant injection | ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma | 160 | 2026-03-17 | 2030-03-30 | in 1,318 d | 2026-06-16 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: EXS74539 | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC) | 40 | 2026-04-13 | Mar 2029 | ≤ 954 d | 2026-06-10 |
| PHIL.MI | Philogen S.p.A. | $1.1B | A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate CancerNCT07600554Adverse events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: [68Ga]Ga-OncoACP3 | Prostate Cancer | 20 | 2026-05-27 | Dec 2027 | ≤ 498 d | 2026-06-10 |
| VIR | Vir Biotechnology, Inc. | $1.6B | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerNCT05997615Part 1 and 3a: Number of participants with treatment-emergent Adverse Events (AEs) | Phase 1 | Recruiting | Drug: VIR-5500 · Combination product: ARSI | Hormone-refractory Prostate Cancer | 437 | 2023-08-10 | 2027-09-29 | in 405 d | 2026-06-04 |
| ANGO | Angiodynamics, Inc. | $654M | Pivotal Study of the NanoKnife System for the Ablation of Prostate TissueNCT04972097results2026-06-02Number of Participants With a Negative In-field Biopsy at 12 Months | Not applicable | Completed | Device: Irreversible Electroporation | Prostate Cancer | 121 | 2022-03-29 | 2024-08-14actual | — | 2026-06-02 |
| AZN | AstraZeneca | — | PRostate Olaparib Real World Evidence StudyNCT06031805observationalTime to treatment discontinuation (TTD) | — | Recruiting | — | Metastatic Castration-resistant Prostate Cancer | 300 | 2023-10-11 | 2028-10-13 | in 785 d | 2026-06-02 |
| AZN | AstraZeneca | — | Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerNCT05367440Number of patients with Adverse Events and Serious Adverse Events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide | Metastatic Prostate Cancer | 174 | 2022-06-02 | 2031-04-11 | in 1,695 d | 2026-06-01 |
| MGNX | MacroGenics | $261M | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011Median radiographic progression free survival (rPFS) determined by investigator review. | Phase 2 | Completed | Biological: lorigerlimab · Drug: docetaxel, Prednisone | Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule | 154 | 2023-09-28 | 2026-02-19actual | — | 2026-05-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174 | Phase 1 | Active, not recruiting | Drug: LY4101174 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 490 | 2024-03-05 | Mar 2027 | ≤ 223 d | 2026-05-22 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerNCT07189403Number of Participants Reporting Dose-limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), TEAEs Associated With Treatment Discontinuation, Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI) - All Patients | Phase 1 | Recruiting | Drug: DS9051b | Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer | 40 | 2025-11-04 | 2028-03-01 | in 559 d | 2026-05-22 |
| CORT | Corcept Therapeutics | $12.8B | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerNCT03437941results2026-05-15Number of Patients With One or More Dose-Limiting Toxicity (DLT) | Phase 1/2 | Terminatedsponsor's stated reason: The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the study. | Drug: Exicorilant, Enzalutamide, Placebo | Metastatic Castration-Resistant Prostate Cancer | 39 | 2018-02-20 | 2021-10-13actual | — | 2026-05-15 |
| BTAI | BioXcel Therapeutics Inc | $25M | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.NCT03910660Phase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBRO | Phase 1/2 | Completed | Drug: BXCL701 plus Pembrolizumab, BXCL701 monotherapy | Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma | 98 | 2019-02-12 | 2023-10-31actual | — | 2026-05-15 |
| AMGN | Amgen | $229.9B | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel | Metastatic Castration-resistant Prostate Cancer | 707 | 2024-12-09 | 2029-01-02 | in 866 d | 2026-05-15 |
| AGEN | Agenus Inc. | $339M | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalNCT06751524expanded access | — | Available | Drug: Botensilimab, Balstililmab | Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC), Melanoma, Sarcoma, Ovarian Cancer, Prostate Cancer | — | — | — | — | 2026-05-15 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07244341Part 1: Number of participants with Dose-Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: Valemetostat, Darolutamide | Metastatic Castration-resistant Prostate Cancer | 60 | 2025-12-03 | 2028-01-31 | in 529 d | 2026-05-15 |
| AZN | AstraZeneca | — | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06879041Number of participants with adverse event (AEs) | Phase 1 | Recruiting | Drug: AZD2287, AZD2275, AZD2284 | Metastatic Castration-Resistant Prostate Cancer | 136 | 2025-03-10 | 2029-04-16 | in 970 d | 2026-05-12 |
| XNCR | Xencor, Inc. | $1.9B | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerNCT05005728Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab) | Phase 2 | Completed | Combination product: vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel · Biological: vudalimab monotherapy | Metastatic Castration-Resistant Prostate Cancer | 72 | 2021-10-22 | 2025-06-10actual | — | 2026-05-05 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerNCT05125016Incidence of Dose-Limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: REGN4336, REGN5678 | Metastatic Castration-resistant Prostate Cancer | 228 | 2021-11-30 | 2030-03-28 | in 1,316 d | 2026-05-05 |
| IBRX | ImmunityBio, Inc. | $8.2B | Immunotherapy Before and After SurgeryNCT06765902Event-free survival (EFS) | Phase 2 | Withdrawnsponsor's stated reason: Study was redeveloped into a new protocol | Drug: N-803, ETBX-071, M-CENK | High-risk Prostate Cancer | 0 | 2025-12-15 | 2031-01-31 | in 1,625 d | 2026-05-05 |
| IBRX | ImmunityBio, Inc. | $8.2B | Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.NCT06765954Complete Pathologic Response (CPR) after pre-radiation immunotherapy. | Phase 2 | Withdrawnsponsor's stated reason: Study was redeveloped into a new protocol | Drug: N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells) · Radiation: External Beam Radiation Therapy (EBRT), Androgen Deprivation Therapy (ADT), Post-radiation immunotherapy | High-risk Prostate Cancer | 0 | 2025-12-01 | 2031-01-31 | in 1,625 d | 2026-05-05 |
| PRCT | PROCEPT BioRobotics | $1.2B | WATER IV Prostate CancerNCT06651632Rate of pad use for urinary incontinence | Not applicable | Active, not recruiting | Device: Aquablation Therapy · Procedure: Radical Prostatectomy | Localized Prostate Cancer | 280 | 2025-02-03 | Jul 2027 | ≤ 345 d | 2026-05-04 |
| AZN | AstraZeneca | — | PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian CohortNCT07560215observationalprevalence of HRR mutations in tissue and/or liquid biopsy samples | — | Not yet recruiting | Diagnostic test: Archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling. | Metastatic Prostate Cancer | 100 | 2026-04-30 | 2027-03-31 | in 223 d | 2026-05-01 |
| AZN | AstraZeneca | — | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsNCT05457257results2025-12-19Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR) | Phase 4 | Active, not recruiting | Drug: olaparib, enzalutamide, abiraterone acetate, Prednisone | Metastatic Castration-resistant Prostate Cancer | 43 | 2022-07-29 | 2024-10-22actual | — | 2026-04-21 |
| CELC | Celcuity Inc | $4.6B | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerNCT06190899Phase 1: Assessment of the safety and tolerability of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) | Phase 1/2 | Recruiting | Drug: Gedatolisib, Darolutamide | mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease, Prostatic Neoplasms, Castration-Resistant, Prostate Cancer | 54 | 2024-01-01 | Jan 2028 | ≤ 529 d | 2026-04-13 |
| RADX | Radiopharm Theranostics, Ltd | — | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPCNCT07259213Incidence of treatment emergent adverse events of 161Tb RAD402 (phase 1) (Safety) | Phase 1/2 | Recruiting | Drug: 161Tb RAD402 | Castration-resistant Prostate Cancer | 73 | 2026-03-05 | 2028-11-30 | in 833 d | 2026-04-01 |
| AGEN | Agenus Inc. | $339M | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerNCT03860272Incidence Of Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Drug: Botensilimab, Balstilimab | Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer | 499 | 2019-03-20 | 2025-01-13actual | — | 2026-03-30 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) | Phase 1/2 | Recruiting | Drug: 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | 61 | 2026-02-23 | Dec 2027 | ≤ 498 d | 2026-03-27 |
| CADL | Candel Therapeutics, Inc. | $922M | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000Biodistribution of aglatimagene besadenovec | Phase 2 | Recruiting | Biological: aglatimagene besadenovec + valacyclovir · Radiation: External Beam Radiation Therapy (EBRT) | Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma) | 45 | 2025-10-30 | Aug 2026 | ≤ 11 d | 2026-03-20 |
| GLUE | Monte Rosa Therapeutics, Inc | $1.3B | Study of Oral MRT-2359 in Selected Cancer PatientsNCT05546268Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2D | Phase 1/2 | Active, not recruiting | Drug: Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359 | NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer | 174 | 2022-10-12 | May 2026 | — | 2026-03-03 |
| INMB | Inmune Bio, Inc. | $59M | Study of INKmune in Patients With mCRPC (CaRe Prostate)NCT06056791Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC. | Phase 1/2 | Completed | Biological: INKmune | Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC | 12 | 2023-11-30 | 2025-09-10actual | — | 2026-02-27 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate CancerNCT05968599results2026-02-25observationalOverall Survival (OS): Adjusted Using Inverse Probability Treatment Weighting (IPTW) | — | Completed | Drug: Enzalutamide, Abiraterone acetate | Prostatic Neoplasms, Castration-Resistant | 2,731 | 2023-07-24 | 2025-02-14actual | — | 2026-02-25 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid TumorsNCT02744287Dose Limiting Toxicity | Phase 1 | Terminatedsponsor's stated reason: Due to a Dose Limiting Toxicity. | Biological: BPX-601 · Drug: Rimiducid | Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | 52 | 2016-11-30 | 2023-03-14actual | — | 2026-02-23 |
| AZN | AstraZeneca | — | Study of AZD0754 in Participants With Metastatic Prostate CancerNCT06267729Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs). | Phase 1/2 | Recruiting | Biological: AZD0754, AZD2287 | Metastatic Prostate Cancer | 60 | 2024-03-12 | 2026-11-24 | in 96 d | 2026-02-23 |
| MGNX | MacroGenics | $261M | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117results2026-02-09Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator | Phase 2 | Terminatedsponsor's stated reason: Business reasons | Biological: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine · Drug: Abiraterone, Enzalutamide | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma | 192 | 2023-06-13 | 2024-07-04actual | — | 2026-02-09 |
| PFE | Pfizer | $155.3B | Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007results2026-01-29observationalBody Mass Index (BMI) | — | Completed | Drug: abiraterone, enzalutamide, docetaxel, apalutamide, cabazitaxel, Radium-223, Lutetium-177, degarelix, goserelin, leuprorelin, triptorelin | Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC) | 1,083 | 2023-02-13 | 2024-04-10actual | — | 2026-01-29 |
| PRCT | PROCEPT BioRobotics | $1.2B | PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTsNCT06051942Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment | Not applicable | Active, not recruiting | Device: Robotic Waterjet Treatment | Benign Prostatic Hyperplasia, Localized Prostate Cancer | 125 | 2022-11-22 | Jul 2026 | — | 2026-01-28 |
| PFE | Pfizer | $155.3B | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerNCT02003924results2018-07-12Metastasis Free Survival (MFS) | Phase 3 | Completed | Drug: Enzalutamide, Placebo | Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate | 1,401 | 2013-10-31 | 2017-06-28actual | — | 2026-01-27 |
| BMY | Bristol-Myers Squibb | $134.9B | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerNCT03338790results2022-02-09Objective Response Rate Per Prostate Cancer Clinical Trials Working Group 3 (ORR-PCWG3) | Phase 2 | Completed | Biological: nivolumab · Drug: docetaxel, enzalutamide, rucaparib, prednisone | Prostate Cancer | 292 | 2017-12-19 | 2021-01-13actual | — | 2026-01-27 |
| AMGN | Amgen | $229.9B | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerNCT06555796Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Drug: Xaluritamig | Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer | 50 | 2024-09-23 | 2026-10-08 | in 49 d | 2026-01-26 |
| IPN.PA | Ipsen | $15.5B | Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist TherapyNCT03516110observationalQuality of Life (QOL) as evaluated by Quality of Life Questionnaire-Elderly 14 items (QLQ-ELD-14) | — | Completed | Other: Data collection | Prostate Cancer | 831 | 2018-03-09 | 2020-02-28actual | — | 2026-01-23 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | 2025-07-21 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Prostate Cancer is matched — 41 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Prostate Cancer
- Prostatic Neoplasms
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Cancer of the Prostate
- Castration-resistant Prostate Cancer
- Prostate Cancer Metastatic
- Metastatic Castration Resistant Prostate Cancer
- Prostatic Cancer
- Castrate Resistant Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Prostate Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Castration Resistant Prostate Cancer
- Advanced Prostate Cancer
- Castrate-Resistant Prostate Cancer
- Castration Resistant Prostatic Cancer
- Castration Resistant Prostatic Neoplasms
- Localized Prostate Cancer
- Prostate Neoplasm
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer
- Castration-Resistant Prostate Cancer (CRPC)
- Hormone Refractory Prostate Cancer
- Hormone Sensitive Prostate Cancer
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Non-Metastatic Prostate Cancer
- Advanced Prostate Adenocarcinoma
- Androgen-Independent Prostatic Cancer
- Androgen-Resistant Prostatic Cancer
- Castration-Resistant Prostatic Cancer
- High-risk Prostate Cancer
- Hormone Refractory Prostatic Cancer
- Hormone-refractory Prostate Cancer
- Locally Advanced Prostate Cancer
- Metastatic Castrate Resistant Prostate Cancer
- Neuroendocrine Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
- Prostate Carcinoma
- Prostatic Neoplasm
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Prostate Cancer” (a text search, wider than this page)